- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15:18 | Telomir completes acquisition of TELI Pharmaceuticals | 2 | Investing.com | ||
| 15:10 | Telomir schließt Übernahme von TELI Pharmaceuticals ab und sichert sich globale Rechte an Telomir-1 | 2 | Investing.com Deutsch | ||
| 15:00 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 | 72 | ACCESS Newswire | Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI... ► Artikel lesen | |
| 14:00 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Telomir seeks FDA approval for Telomir-1 to treat breast cancer | 19 | Pharmaceutical Technology | ||
| 31.03. | Telomir reicht IND-Antrag für Krebsmedikamentenkandidaten ein | 1 | Investing.com Deutsch | ||
| 31.03. | Telomir submits IND application for cancer drug candidate | 1 | Investing.com | ||
| 31.03. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 in Advanced and Metastatic Triple-Negative Breast Cancer | 180 | ACCESS Newswire | First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir... ► Artikel lesen | |
| 31.03. | Telomir Pharmaceuticals beantragt FDA-Zulassung für Brustkrebs-Medikament Telomir-1 | 2 | Investing.com Deutsch | ||
| 27.03. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.03. | Telomir Pharmaceuticals, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 17.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models | 315 | ACCESS Newswire | Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)... ► Artikel lesen | |
| 17.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging | 746 | ACCESS Newswire | Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic... ► Artikel lesen | |
| 05.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.01. | Rodman & Renshaw initiates Telomir Pharma stock with Buy rating | 1 | Investing.com | ||
| 05.01. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models | 346 | ACCESS Newswire | In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire... ► Artikel lesen | |
| 05.01. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Telomir Pharmaceuticals beschließt neues Vergütungspaket für CEO | 3 | Investing.com Deutsch | ||
| 18.12.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | 379 | ACCESS Newswire | No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,85 | -0,61 % | BioNTech Aktie: Kurs dreht auf! Zulassungsantrag, Pipeline-Power und ein Einstiegssignal! | © Foto: Pexels (Symbolbild)Lange war BioNTech für viele Anleger ein Sorgenkind. Der Rückgang des Corona-Geschäfts drückte auf den Kurs, der Abgang der Gründer sorgte für Unsicherheit. Dann kam der Absturz... ► Artikel lesen | |
| MODERNA | 43,460 | -3,85 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| VALNEVA | 2,326 | -2,31 % | ALARMSTUFE ROT bei Valneva: Könnte die Aktie jetzt komplett einbrechen? - Meine klare Einschätzung dazu | ||
| OCUGEN | 1,394 | -2,79 % | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead | ||
| INOVIO PHARMACEUTICALS | 1,008 | +2,86 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,300 | +0,71 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| BAVARIAN NORDIC | 24,960 | +0,08 % | Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S | COPENHAGEN, Denmark, April 21, 2026 - Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors'... ► Artikel lesen | |
| GERON | 1,337 | +3,73 % | Geron Corporation: Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 | ||
| IMMUNITYBIO | 6,500 | -7,41 % | ImmunityBio startet Vertrieb von Krebsmedikament Anktiva in Saudi Arabien | ||
| IOVANCE BIOTHERAPEUTICS | 2,985 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| ZAI LAB LTD ADR | 18,600 | -0,53 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| VERASTEM | 5,136 | -3,75 % | H.C. Wainwright reiterates Verastem stock rating on durable trial data | ||
| APELLIS PHARMACEUTICALS | 34,830 | -0,54 % | Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on | ||
| ADMA BIOLOGICS | 11,355 | +2,53 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| XENON PHARMACEUTICALS | 46,400 | -2,11 % | Xenon Pharmaceuticals Inc.: Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting | Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,59 % bei einem Aktienkurs von 1,385 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.